Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.

被引：2
|
作者：
Carlino, Matteo S.
Ascierto, Paolo Antonio
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean Jacques
Hauschild, Axel
Kirkwood, John M.
Long, Georgina V.
Mohr, Peter
Robert, Caroline
Ross, Merrick I.
Scolyer, Richard A.
Sondak, Vernon K.
Yoon, Charles
Poklepovic, Andrew Stewart
Rutkowski, Piotr
Anderson, James R.
Ahsan, Sama
Ibrahim, Nageatte
Luke, Jason J.
机构：
[1] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[4] Gustave Roussy Canc Ctr, Paris, France
[5] Univ Paris Saclay, Paris, France
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, Marseille, France
[8] Univ Hautklin Kiel, Kiel, Germany
[9] Univ Pittsburgh, UPMC Hillman Canc Ctr, Melanoma Program, Pittsburgh, PA USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Sydney, NSW, Australia
[12] Mater Hosp, Sydney, NSW, Australia
[13] Elbe Kliniken Buxtehude, Buxtehude, Germany
[14] Gustave Roussy, Villejuif, France
[15] Paris Sud Univ, Villejuif, France
[16] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
[20] VCU Massey Canc Ctr, Richmond, VA USA
[21] Maria Sklodowska Curie Inst, Warsaw, Poland
[22] Merck & Co Inc, Kenilworth, NJ USA
[23] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS9596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9596
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma
    Geiger, Jessica
    Daniels, Gregory
    Cohen, Ezra
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona
    Chang, Anne Lynn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high risk, locally advanced cutaneous squamous cell carcinoma.
    Geiger, Jessica Lyn
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona F.
    Chang, Anne Lynn S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Scherrer, Emilie
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    CLINICAL DRUG INVESTIGATION, 2020, 40 (07) : 629 - 643
  • [24] An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
    Arielle G. Bensimon
    Zheng-Yi Zhou
    Madeline Jenkins
    Yan Song
    Wei Gao
    James Signorovitch
    Clemens Krepler
    Emilie Scherrer
    Jingshu Wang
    Raquel Aguiar-Ibáñez
    Clinical Drug Investigation, 2020, 40 : 629 - 643
  • [25] KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma
    Long, Georgina V.
    Eggermont, Alexander M.
    Gershenwald, Jeffrey E.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Dummer, Reinhard
    Hauschild, Axel
    Carlino, Matteo S.
    Ribas, Antoni
    Robert, Caroline
    Scolyer, Richard A.
    Sondak, Vernon K.
    Cohen, Jonathan E.
    Zhang, Jinchun
    Grebennik, Dmitri O.
    Krepler, Clemens
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harheck, Nadia
    Telli, Melinda L.
    Cescon, David W.
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Gonzalez Fernandez, Manuel
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S4 - S5
  • [27] Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
    Grossmann, Kenneth F.
    Othus, Megan
    Patel, Sapna P.
    Tarhini, Ahmad A.
    Sondak, Vernon K.
    Knopp, Michael, V
    Petrella, Teresa M.
    Truong, Thach-Giao
    Khushalani, Nikhil, I
    Cohen, Justine, V
    Buchbinder, Elizabeth, I
    Kendra, Kari
    Funchain, Pauline
    Lewis, Karl D.
    Conry, Robert M.
    Chmielowski, Bartosz
    Kudchadkar, Ragini R.
    Johnson, Douglas B.
    Li, Hongli
    Moon, James
    Eroglu, Zeynep
    Gastman, Brian
    Kovacsovics-Bankowski, Magdalena
    Gunturu, Krishna S.
    Ebbinghaus, Scot W.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sharon, Elad
    Korde, Larissa A.
    Kirkwood, John M.
    Ribas, Antoni
    CANCER DISCOVERY, 2022, 12 (03) : 644 - 653
  • [28] Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
    Kennedy, Oliver John
    Kicinski, Michal
    Valpione, Sara
    Gandini, Sara
    Suciu, Stefan
    Blank, Christian U.
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Robert, Caroline
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Mandala, Mario
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [29] Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma
    Khattak, A.
    Robert, C.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V.
    Dalle, S.
    Haydon, A.
    Lichinitser, M.
    Carlino, M. S.
    Sandhu, S.
    Larkin, J.
    Puig, S.
    Ascierto, P. A.
    Rutkowski, P.
    Schadendorf, D.
    Lorigan, P.
    Ibrahim, N.
    Suciu, S.
    Eggermont, A. M. M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 48
  • [30] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda
    Cescon, David
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
12345